PATHUiPath Inc

$PATH has been attracting renewed investor attention as optimism builds around enterprise automation and AI-powered software. As businesses continue looking for ways to improve productivity and reduce costs, robotic process automation remains an important long-term trend. With AI becoming more integrated into enterprise workflows, investors are watching whether UiPath can accelerate growth and strengthen its position in the automation market. Do you think UiPath can become one of the biggest long-term winners in enterprise AI, or is the competition becoming too intense?

it's really interesting to see how robotics and security performed this past month as $PATH catches a nice tailwind from the ai trend. $S is also showing how critical cybersecurity remains for every enterprise tech stack right now. do you think this momentum will keep up through the next quarter?

Hunch Buying techniques on the highest percentages will actually loose.  $NFLX $CMG $NKE $TTD $TSLA $IRDM $ACHR $RR $SPY $GDLC $SNPS $NVDA $TGT $FTNT $PLUG $PATH   $MRNA  These are the stocks that right now , which i see based on certain factors, fundamentals and technical prices can be  a ideal investment. 

Portfolio Snapshot – Strategy & Rationale

This portfolio avoids chasing short-term percentage gainers. Positions are built around durable leaders, selective growth, and asymmetric technology bets, with controlled exposure to mega-caps.

Core / Quality Tilt (not over-weighted):

• NFLX, CMG, NKE – Proven execution, pricing power, brand durability

• SNPS, NVDA – Infrastructure beneficiaries of long-cycle AI adoption

• SPY – Market baseline, volatility buffer

Growth & Tech Expansion:

• TTD, FTNT, IRDM – Scalable platforms with recurring revenue and niche dominance

• TSLA – Optionality across energy, autonomy, and manufacturing efficiency

Asymmetric / Emerging Tech:

• ACHR, Richtech Robotics (RR), PLUG, PATH – Early-stage or turnaround plays where downside is defined but upside is non-linear

Thematic / Diversifiers:

• MRNA – Platform biotech with pipeline optionality

• TGT – Cyclical recovery with valuation support

• GDLC – Digital asset exposure without single-coin risk

This is for informational purposes only. Always perform thorough research and consider your financial situation before making investment decisions. Consider revising it with your own advisors based on life events.

 Investments carry risks, and you may lose value, including your principal investment or your investment might become zero.

Which of these stocks are at inflection point with breakthrough in technology, scaling operations, expanding revenue and finally becoming viable long term story.

And which will likely end as its do or die year for them and likely to die.

1. $ASTS

2. $JOBY

3. $RKLB

4. $LUNR 

5. $RDW

6. $SOFI

7. $ABAT

8. $EOSE

9. $AUR

10. $POET

11. $QS

12. $NVTS

13. $RCAT 

14. $KRKR

15. $PL

16. $TE

17. $PGPKY

18. $PATH 

19. $NBIS 

20. $ONDS